Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on Monopar Therapeutics Inc. (NASDAQ:MNPR) on June 29, 2026.
reiterateNASDAQ:MNPR
HC Wainwright & Co. Reiterates Buy Rating on Monopar Therapeutics Inc. (MNPR)
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on Monopar Therapeutics Inc. (NASDAQ:MNPR) on June 29, 2026.
Market Context
Monopar Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $94.56 with a market capitalization of $514.6M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Monopar Therapeutics Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Monopar Therapeutics Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 29, 2026 | HC Wainwright & Co. | Buy | N/A |
| Mar 30, 2026 | Chardan Capital | Buy | N/A |
| Feb 23, 2026 | BTIG | Buy | N/A |
| Feb 02, 2026 | BTIG | Buy | N/A |
| Jan 29, 2026 | Chardan Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View MNPR Stock Page
Frequently Asked Questions
What does a Buy rating mean for MNPR?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on Monopar Therapeutics Inc. (NASDAQ:MNPR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MNPR forecast page.